Try our Advanced Search for more refined results
Life Sciences - July, 2016
330 articles
- WL Gore Can't Recover Lost Profits In Stent IP Row: Judge
- Celesio, Sainsbury's Pharmacy Deal Gets UK Approval
- Otsuka's 'Convoluted' Logic Spurned In Abilify Maintena Row
- Bausch & Lomb Eye Drop Patents Survive AIA Review
- NJ Merck Workers Suspend FLSA Suit Amid Settlement Talks
- Pair Admits To Illegal Money Moves After Meningitis Deaths
- United Healthcare Sues Cephalon Over Provigil Pay-For-Delay
- Product Liability Regulation & Legislation: Midyear Report
- EPA Won't Rethink Bayer's Challenge To Axed Pesticide
- Health Hires: Cooley, Lowenstein, Foley Grow Life Sci Teams
- Fed. Circ. Says PTAB Was Wrong To Uphold Zoll Patent
- IK Investment Partners Sells Dutch OTC Drug Co. Vemedia
- A 'Smoking Gun' In Reverse-Payment Settlements
- Shedding Further Light On The FCPA Pilot Program
- Merck Asks Supreme Court To Hear PTAB Deference Row
- Prevent Litigation From Becoming A Threat To Data Security
- PTAB Nixes 6 Jazz Pharma Patents In AIA Reviews By Rivals
- J&J Denied Bid For Speedy 5th Circ. Appeal In Hip MDL
- More Expert Testimony Allowed In 1st Tylenol Bellwether
- Bayer Beats 1,200 Suits Over Mirena IUD Injuries
- Millennium Fights $5M HIPAA Coverage Loss At 9th Circ.
- Judge Won't Change $70M Jury Verdict Against Neovasc
- SynCardia Creditors Worried Over DIP, Bidding Orders
- Deals Rumor Mill: Allegro, Zabka Polska, InVentiv Group
- DLA Piper Atty Wants Sanction, Contempt Order Lifted
- Medical Device Co. To Pay $11.5M Over Alleged Kickbacks
- Fosun To Buy KKR-Backed Indian Drug Co. For Up To $1.3B
- Pharma Co. Hit With Bias Suit From Ex-Global Study Leader
- Par Pharma Sued For Abusing Monopoly Of Vasopressin
- Corporations In The Crosshairs Of Product Liability Claims
- OPINION: Our Juries Are Being Circumvented
- Benicar MDL Partially Remanded To Missouri State Court
- Supplement Co. Loses Wash. Tax Liability Appeal
- Watson Pushes To Sever Lidoderm, Opana Pay-For-Delay Suits
- Democratic Leaders Want In On FDA's Theranos Probe
- Momenta Wins Dismissal Of Blood-Clot Drug Antitrust Suit
- 3rd Circ. Won't Touch Avandia MDL Fee Ruling
- Bind Therapeutics Wins OK Of $40M Ch. 11 Sale to Pfizer
- High Court Lifts Stay On Merck Birth Control Patent Ruling
- Mylan Must Divest Two Generics To Buy Meda, FTC Says
- Bernstein Litowitz Rips Subpoena In Insider Trading Row
- FTC Clears Teva's $40.5B Generics Buy With Divestitures
- Colorado Pot Shop Fights IRS To Restore Tax Write-Offs
- Kadmon Prices IPO Below Range While Tactile Cuts Deal Size
- Deals Rumor Mill: Gland Pharma, SoundCloud, Xplornet
- Cost Of Wasted Eye Drops Counts As Harm, 3rd Circ. Told
- The Internet Of Health Things: Privacy And Security Issues
- Legal Aid, Meet Legal Tech
- 4 Traits Of The Top Litigation Firms
- 5 Small(er) But Mighty Litigation Shops
- Law360 Names Top 50 Firms For Litigation
- J&J Can't Speed Up Appeal In Hip MDL, Patients Tell 5th Circ.
- J&J Can't Nix Causation Experts In 1st Tylenol Bellwether
- Pa. Judge Won't Ax $70M Risperdal Breast-Growth Verdict
- FDA Updates Warnings For Antibiotics Class
- Drugmakers Say Rulings Don't Back Chicago Opioid Case
- Pharma Researcher Must Face Investor Suit Over Outage
- Deals Rumor Mill: Permira, Wako Pure Chemical, TransCanada
- Fed. Circ. Axes Illumina Bid To Arbitrate Ariosa Patent Row
- FDA Warning Wire: 'Slimy Build-Up' At Big Salad Co.
- Vertex Ignored Red Flags In Clinical Trial, 1st Circ. Told
- Arizona Ends 6-Year Freeze On CHIP Enrollments
- Mylan Wins PTAB Review Of Pfizer's Toviaz Patents
- Valeant, Par End Patent Suit Over Colitis Treatment
- Recent Off-Label Device Cases Are A Road Map For The Future
- Testing The UBE: Portable But Inaccurate Bar Exam Scores
- Couple Indicted After Meningitis Outbreak Want Charges Axed
- Eye Drop Dose Suit Against Allergan, Others Wins Class Cert.
- CVS' Vitamin E Actually Bad For Heart, 1st Circ. Told
- Brand Battles: Apple, Bristol-Myers, Novartis, Subway
- Consumers Fight Pfizer Bid To Escape Lipitor MDL
- Otsuka Asks 6th Circ. For Relief From Abilify FCA Suit
- CytRx Hit With Investor Suit Related To FDA Hold On Drug
- Paul Hastings Adds IP, Antitrust Pro From Patterson Belknap
- Merck Urges 9th Circ. To Reject Diabetes Drug Warning Claims
- FTC Fights To Preserve Gray Hair Supplement False Ad Suit
- Benefiting From FDA's Medical Device Risk-Benefit Guidance
- Teva, Forest Settle Patent Fight Over $759M Namenda XR
- Device Cos. Decry DOJ 'Smears' Amid Fraud Inquiry
- Ironshore Can't Escape 23andMe Test Accuracy Coverage Spat
- Can Reference Sponsor Forfeit Right To Sue Under BPCIA?
- Testing The UBE: Missouri Benefits From Uniform Bar Exam
- Minor Convictions In Acclarent Trial Raise Major Questions
- Taxation With Representation: MoFo, Davis Polk, Cooley
- NBTY Vitamins Falsely Labeled 'Made In USA,' Consumer Says
- CORRECTED: Medtronic IP Expert Dinged For Lack Of Mind-Reading Prowess
- Amgen's 'Pointless' Biosimilar Pathway Suit Gets Axed
- Drugmaker Can't Deny Contract, Then Sue Over It, Judge Told
- Roche Wins Appeal Of $18M Verdict In Accutane Suit
- High Court Stays Merck Birth Control Patent Ruling
- Calif. CVS Pharmacists Not Paid For Training, Suit Says
- NJ Man Gets 30 Mos. In $1M Corporate Embezzlement Scheme
- J&J Unit Settles Sinus-Device FCA Suit For $18M
- Anti-Zika Spray Will Hurt Citizens, Puerto Rico Mayor Says
- Generic Drug Price Surges Don't Always Point To Collusion
- J&J Unit Fails To Overturn $8M Hip Implant Verdict On Appeal
- Fed. Circ. Kills $20M AngioScore Win For Jurisdiction Flub
- Class Fee In $7.2B Receptos Merger Suit Slashed To $100K
- Foot Care Co. Can Appeal Trademark Verdict, Judge Rules
- AstraZeneca Sues Aurobindo For Nexium Patent Infringement
- Jones Day, Latham Guide Galenica's $1.5B Relypsa Buy
- Teva Sells Additional $5.4B In Bonds To Buy Allergan Unit
- Deals Rumor Mill: Shenhua Group, Engie, Fresenius
- Abbott Can't Put Depakote Blame On FDA, Mom Tells 6th Circ.
- Warner Chilcott, Zydus Face Leaner Product-Hop Suit
- Doc Accused Of Bribing Sen. Wants $2M Put In Fees Trust
- Boston Scientific Reaches $275M Settlement With IRS
- Dr. Reddy's Countersuit Rejected In Purple Pill Trademark Row
- PE-Backed Drug Services Firm, Tech Co. Net $692M In 2 IPOs
- Archer Daniels Faces Class Action Over Deadly Horse Feed
- Ethicon Says Professor Unfit To Testify In Pelvic Mesh MDL
- USPTO Cancer Drug Pilot Program Not Likely To Be Used Much
- Amgen To Pay $95M In Class Action Securities Settlement
- Mylan's Proposed Acquisition Of Meda Receives EU Approval
- Surgery Center Can't Trim Meningitis MDL, Tenn. Judge Told
- Fed. Circ. Revives Heart Rate Monitor Patent Row In Del.
- Endo Fluoride Labeling Suit Survives Dismissal Bid
- Diabetes Test Co. Says Jury Right To Deny $1M In Legal Fees
- 7th Circ. 'Pill Mill' Ruling Ushers In Nuisance Coverage
- Medical Supply Co. Wants Sanctions Over Patent Suit
- Celgene Paying Up To $2.6B In Jounce Cancer Collaboration
- Deals Rumor Mill: BC Partners, Mondelez, Clariant
- States Emboldened In Suboxone Antitrust Row After Namenda
- 5 States Clearing The Smoke On Pot Ethics Rules
- Ex-Acclarent Execs Beat Felony Off-Label Fraud Charges
- Merck Asks To Wait For Fed. Circ. In Gilead Atty Fees Row
- XY Urges Court To Consider Halo In Sex-Selection IP Case
- Pfizer Reaches Settlement In Drug-Risk Securities Suit
- AstraZeneca Loses Bid To Keep FDA OK From Generic Crestor
- Teva Settles Drug Patent Row With Celgene, Astellas
- Teva Sells $15B In Bonds To Help Fund Actavis Generics Deal
- Atty Must Give Law School Lectures As Punishment
- FDA Warning Wire: Penicillin Contamination And Cockroaches
- Deals Rumor Mill: Yahoo, Monsanto, Silver Run
- Ex-Morgan Stanley Broker Inks Sanofi Insider Trading Deal
- Stock Prices Aren't Enough For 'Rule Of Reason' Analysis
- Perrigo Investor Slams Co. Over Mylan's Failed Takeover
- Insurance Co. Must Defend 'Pill Mill' Suit, 7th Circ. Says
- Faulty Blood Test Suits Pile Up Against Theranos, Walgreens
- Ameritox Awarded $1.1M In Interest For Patent Case
- Fed. Circ. Clarifies Doctrine Of Equivalents In ANDA Litigation
- Monsanto Spurns Bayer's Sweetened Offer
- Icahn Urges 2nd Circ. To Affirm Toss Of Insider Trading Suit
- Warner Chilcott Can't Nix Pay-For-Delay Row: Loestrin Buyers
- Ex-Pharma Exec Wins Appeal To Not Arbitrate Wage Row
- Pa. Judge Won't Nix Tylenol Causation Study From MDL
- Eli Lilly Says Brazil Entity Covered In Contamination Row
- Feds Say NY Court Can't Rule On Pfizer's $8.3M Interest Row
- J&J Talcum Powder Suits Should All Go To Ill., JPML Told
- Applying Cartier V. BSkyB To UK Life Sciences Patents
- Fed. Circ. Denies Rehearing In Merck Patent Loss Case
- Skadden Steers Senior Housing Properties Trust's $620M Loan
- How Law Firms Can Create Next-Generation Office Spaces
- GlaxoSmithKline Denied Bid To Unpause Philly Paxil Litigation
- Feds Launch Internal Review Of Failed FedEx Criminal Case
- Retailers Say Birth-Control Drugmaker Stifled Generics
- Stunted-Chicken Ruling Hatches Fight Over Defect Exclusions
- USPTO Tells Examiners In Vitro Patent Ruling Clarifies Mayo
- Bayer Wants Dow Appeal Of $456M Crop Science Award Killed
- Health Hires: New Attys At PhRMA, Nelson Mullins, McDermott
- Ex-Acclarent Exec Takes Aim At FDA In Closing
- Generics Giant Teva Joins PhRMA, Shaking Up Brand Lobby
- NY Judge Looks To Trim Impax AIDS Drug Suit Against Turing
- Indivior Expects Product-Hopping Claims From 25 States, DC
- GSK, Indirect Purchasers Plan To Settle Pay-For-Delay Suit
- Smokers' Rights Groups Sue FDA Over New Tobacco Regs
- Taxation With Representation: Paul Weiss, Kirkland, Simpson
- PTAB Nixes Claims In Blue Belt Surgical Robotic Patent
- Deals Rumor Mill: Enbridge, Williams Cos., Walgreens
- Herbalife Seals $200M FTC Deal, Hires Davis Polk
- AbbVie Urges Judge To Nix FTC's Bid For 'Irrelevant' Info
- As Science Evolves, So Must Political Risk Insurance
- Halo Magnifies Patent Infringement Risks In M&A
- Why The Florida Supreme Court Shouldn't Undo Daubert
- Atty Sues Firms Over Share Of $30M Bristol-Myers Settlement
- Lipozene Class Cert. Process Should Go Forward, Court Told
- Tibet Pharma Investors Ask Court To Dismiss IPO Suits
- 3rd Circ. Free To Nix SEC Deal Post-Newman, Ex-Exec Says
- Jury Hears Rival Portraits Of Acclarent Execs In Fraud Trial
- Bayer Raises Buyout Offer To Entice Monsanto
- NJ Court Axes Insurer Win In Stunted-Chicken Coverage Fight
- Shkreli Wants To Sever Fraud Case From Ex-Kaye Scholer Atty
- Fed. Circ. Affirms Celgene Win In Bone Cancer Drug IP Case
- Deals Rumor Mill: Teva, Berkshire Hathaway, MBK Partners
- AbbVie's Biosimilar Criticisms 'Lack Merit,' FDA Says
- FTC Approves Invibio Monopoly Abuse Settlement
- An Update On Spoliation Sanctions Under Rule 37(e)
- FDA's Guidance On Medical Device Data Needs Improvement
- Pa. Cancer Center's Licensing Breach Claims Trimmed
- Texas AG Says Pharmacy Choice Rule Not Yet Enforceable
- J&J Asks 5th Circ. To Hurry Hip MDL Appeal
- Senate Passes Anti-Opioid Abuse Funding, Reform Bill
- Deals Rumor Mill: Jamieson Laboratories, Symantec, Carlyle
- Spectrum Settles Cancer Drug Patent Row With Fresenius
- Paul Hastings Scoops Up 2 Ropes & Gray IP Partners
- Travelers Denied Reconsideration Bid In $167M Coverage Row
- US Lawmakers Express Doping Enforcement Concerns To IOC
- Supplement Maker Slammed Over Allegedly Toxic Drink
- Seeger Weiss' Vioxx Deal Doesn't Bar Suit, 5th Circ. Told
- J&J Urges Pa. Judge To Nix $70M Risperdal Verdict
- Life Sciences Cases To Watch In The 2nd Half Of 2016
- AstraZeneca OKs Sandoz Cancer-Drug Generic For 2019
- Chicago Says Monster Energy Drink Ruling Backs Opioid Case
- Drug Cos. Say Lidoderm, Opana Pay-For-Delay Suit Improper
- FDA Overreaching With Tobacco Rule Expansion: E-Cig Cos.
- On Sale At Fed. Circ.: Clarity For Patent Invalidity Claims
- LabMD Draws Law Firms, Coke Into Tiversa Data Theft Row
- Anda Asks 11th Circ. To Return Coverage In 'Pill Mill' Case
- Sports Supplement Co.'s False Ad Suit Tossed
- GNC Says Investors Can't Back Up Illegal Drug Suit
- NJ Couple Must Pay $7.5M Judgment For Medicare Fraud
- BioArray Moves Rutgers IP Licensing Suit To Federal Court
- Jury Verdict Alone Enough For Willfulness Post-Halo: Judge
- Paragon BioTeck Blasts Eye Drop Supplier's Exec At PTAB
- Atty Tells 11th Circ. DOJ Cheated To Get His Fraud Conviction
- Impax Looks To Duck Endo's $100M Suit Over Drug Licensing
- Size Matters In Approving Pay-For-Delay Class, 3rd Circ. Told
- Lipozene Buyer Fights Maker's Bid To Toss False Ad Suit
- The Importance Of Adequate M&A Disclosures To Stockholders
- Valeant Unit Settles Sex Discrimination Claims For $7.2M
- Mylan Infringed Forest's Savella Drug Patents, Judge Rules
- PTAB Finds Becton's Remote Pharmacy Patent Obvious
- Gilead AIDS Drug Antitrust Case To Get Appeal
- P&G Seeks To Scrub Fixodent MDL After Experts Nixed
- Investors Accuse Stericycle Of Inflating Profits Through 'Fraud'
- Skyrocketing FCA Penalties Ripe For Constitutional Challenges
- Fed. Circ. Unfreezes Biotech Patents In CellzDirect
- OPINION: Stop Pharma Hopping Mischief
- Bard Says Jury Shouldn't Decide Triple Damages Bid In IP Suit
- Amgen Opens Trial In Fight Over Neulasta Generic
- Fed. Circ. Ruling Blunts On-Sale Bar's Threat To Patents
- Insurance Co. Says Testosterone Marketing Suit Must Stand
- Sandoz's Enbrel Biosimilar Gets FDA Staff Nod
- A Primer On Anda's 'Pill Mill' Coverage Battle With Travelers
- Federal Gov't Won't March In When It Comes To Drug Prices
- Lipocine Lied About Testosterone Pill's Chances, Investors Say
- Japanese Drug Co. To Pay $736M For US Generics Maker
- Boiron Says Jury Verdict Is Binding In False Ad Row
- How To Close A Law Firm — Practically And Ethically
- Anthem Slams Express Scripts Claims In $13B Pricing Row
- PE Firms Pay $3.55B For Thomson Reuters' IP, Science Unit
- Full Fed. Circ. Limits On-Sale Bar's Reach In Angiomax Case
- The First 90 Days Of DOJ's FCPA Pilot Program
- Becton Says New Evidence Justifies $167M Travelers Row
- Life Sciences Patents Boosted By Fed. Circ. Take On Mayo
- New States Fight Obama Transgender Policy, Big Biz Supports
- GSK Unit Pushes Back On SEC In Stock Fraud Suit
- Amgen's Humira Biosimilar Wins FDA Staff Support
- Acclarent Execs Ask Judge To Halt 'Confusing' Prosecution
- Buchanan Nabs Milbank Pharma, Import IP Pro
- Abbvie's Humira Patent Claims To Be Reviewed By PTAB
- FDA Offers Guidance For Updating Some Generic Labels
- Celator Reaches Deal In Suits Over $1.5B Sale To Jazz
- Merck Wants Genentech's Cancer Drug Patent Invalidated
- Celgene Tells Fed. Circ. Chemo IP Row Deserved Dismissal
- More Than 100 Plaintiffs Need New Attys In Zimmer MDL
- Boehringer Offers Fixes To Clear Sanofi Deal In EU
- After-Developed Defenses Still Relevant After Halo
- Illumina Settles DNA Patent Row With Enzo For $21M
- Taxation With Representation: Wachtell, Skadden, Orrick
- Limitations On Direct-To-Consumer Tests In Md. And NY
- Theranos CEO Holmes Gets 2-Year Lab Ownership Ban
- Atty Fees In Amerisource Shareholder Deal To Be Reworked
- St. Jude Ends Investor Suit Over Cardiac Devices For $39M
- Hospira, Amgen Duel Over Biosimilar Ruling's Impact
- FDA Cold On Freezing Treatments
- Medco Says Relator Brings Nothing New To FCA Case
- EU High Court Says Law Allows Royalties For Invalid Patents
- KaloBios Strips Ex-CEO Shkreli Of Shareholder Power
- Halo Saves $131M Verdict Against Cochlear, Fed. Circ. Told
- Evolving Insurance Coverage For Nanotechnology Risks
- The Smart Money Is Not Following Traditional Law Firms
- Bayer Admissions Can Carry IUD Claims, Consumers Say
- NJ Drug Co. Pleads Guilty To Gel Contamination Charges
- You Can't 'Patent Dance' Your Way Out Of Biosimilar Notice
- Medtronic Unit Pushes Fed. Circ. To Revive Spinal Implant IP
- GSK Denied Stay In Antitrust Suit Pending High Court Decision
- Gilead Beats Antitrust Suit Over HIV Drug Patents
- FDA Assails AstraZeneca's Attack On Crestor Generics
- Pfizer, Chicago Reach Opioid Marketing Pact
- SynCardia Pushes For Rapid Ch. 11 Sale Process
- Eli Lilly Escapes Cymbalta User's Withdrawal Class Action
- 9th Circ. Wipes Out 7-Year Medicare Fraud Sentence
- Ex-CEO Of Australian Pharma Co. Dodges Securities Suit
- Award In J&J Hip Implant Bellwether Trial Slashed To $150M
- Gilead Wants $15.5M In Fees From Merck After Hep C Upset
- Pharma Cos. Appeal Rejected Subpoena Of Express Scripts
- Hyland Can't Dodge Homeopathic False Ad Claims For Now
- Kirkland & Ellis Guides Ventas In $1.5B Real Estate Deal
- The High Court's Artificial And Fictitious Patent Test: Part 2
- RFP Lessons: 5 Ways Law Firms Can Beat Frustration
- After Verdict Reversal, Gilead Takes Aim At Merck Patents
- J&J, DePuy Can't Put Texas Hip Implant MDL On Hold
- SEC Seeks To Banish Ex-Pharma CEO After Fraud Verdict
- 7th Circ. Upholds Conviction For Unauthorized Drug Sales
- FDA Green Lights Abbott's Dissolving Coronary Stent
- Medivation In Talks With Sanofi After Rejecting Its $9.3B Offer
- Takeda Says USPTO Shorted Life Of Patent For Diabetes Drugs
- Jones Day Snags Latham & Watkins Life Sciences IP Pro
- FDA Warning Wire: Gluten, Rodents, Falsified Records
- Unsealed Lincare FCA Alleges Millions In Medicare Fraud
- Abbott Tells 6th Circ. Depakote Testimony Correctly Limited
- PTAB Wrong To Reject Flu Med IP, Fed. Circ. Hears
- Fed. Circ. Revives In Vitro's Cell Preservation Patent
- Pfizer Unit's Antibiotic Patent Faces Fed. Circ. Challenge
- FTC Says AbbVie Must Produce Board Docs In AndroGel Fight
- Deals Rumor Mill: Aetna, Marken, Iliad
- Chinese Pharma Firm Raises $150M From Private Investors
- Artificial Heart Maker Plans Quick Ch. 11 Sale Process
- Biosimilar Notice Always Mandatory, Fed. Circ. Rules
- The High Court's Artificial And Fictitious Patent Test: Part 1
- Kirkland Guides Bristol-Myers' $520M Cancer Drug Co. Buy
- RFP Lessons: 7 Tips To Improve Your Responses
- Inventor In Spinal Drug Row Asks Justices To Allow New Docs
- Quinn Emanuel To Bat For Elan Classes In SAC Trial
- Tyco Wants Attys' Fees After Win In $60M Drug Heist Suit
- Beleaguered Theranos' Bad Lab Tests Queried By Dems
- Health Hires: Greenberg, Covington Add IP, Deals Pros
- Consumers Eye Deal On Documents In Contact Lens MDL
- Justices Urged To Take Up FCA Row Over Bayer Anthrax Drug
- Dopamine Agonist Drugs Need Compulsion Warning: Group
- 1st Circ. Upholds Dismissal Of FCA Suit Against CVS
- Feds Blast Easing Of House Arrest For Exec Murder Suspect
- CPSC Chair Praises Industry Push For Window Blind Safety
- 2nd Circuit Affirms Tossing Mirena Claims Against Bayer
- Czechs Ask Full DC Circ. To Flip Panel's OK Of $325M Award
- KaloBios Emerges From Ch. 11 With Chagas Drug Rights
- J&J Unit Slammed With $70M Verdict In Philly Risperdal Trial
- Diagnosing The Sequenom Problem
- RFP Lessons: A General Counsel's List Of Law Firm Mistakes